Icelandic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
European Journal of Radiology 2019-May

Prediction of molecular subtypes of breast cancer using BI-RADS features based on a "white box" machine learning approach in a multi-modal imaging setting.

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Krækjan er vistuð á klemmuspjaldið
Mingxiang Wu
Xiaoling Zhong
Quanzhou Peng
Mei Xu
Shelei Huang
Jialin Yuan
Jie
Tao Tan

Lykilorð

Útdráttur

To develop and validate an interpretable and repeatable machine learning model approach to predict molecular subtypes of breast cancer from clinical metainformation together with mammography and MRI images.We retrospectively assessed 363 breast cancer cases (Luminal A 151, Luminal B 96, HER2 76, and BLBC 40). Eighty-two features defined in the BI-RADS lexicon were visually described. A decision tree model with the Chi-squared automatic interaction detector (CHAID) algorithm was applied for feature selection and classification. A 10-fold cross-validation was performed to investigate the performance (i.e., accuracy, positive predictive value, sensitivity, and F1-score) of the decision tree model.Seven of the 82 variables were derived from the decision tree-based feature selection and used as features for the classification of molecular subtypes including mass margin calcification on mammography, mass margin types of kinetic curves in the delayed phase, mass internal enhancement characteristics, non-mass enhancement distribution on MRI, and breastfeeding history. The decision tree model accuracy was 74.1%. For each molecular subtype group, Luminal A achieved a sensitivity, positive predictive value, and F1-score of 79.47%, 75.47%, and 77.42%, respectively; Luminal B showed a sensitivity, positive predictive value, and F1-score of 64.58%, 55.86%, and 59.90%, respectively; HER2 had a sensitivity, positive predictive value, and F1-scores of 81.58%, 95.38%, and 87.94%, respectively; BLBC showed sensitivity, positive predictive value, and F1-scores of 62.50%, 89.29%, and 73.53%, respectively.We applied a complete "white box" machine learning method to predict the molecular subtype of breast cancer based on the BI-RADS feature description in a multi-modal setting. By combining BI-RADS features in both mammography and MRI, the prediction accuracy is boosted and robust. The proposed method can be easily applied widely regardless of variability of imaging vendors and settings because of the applicability and acceptance of the BI-RADS.

Skráðu þig á
facebook síðu okkar

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum

  • Virkar á 55 tungumálum
  • Jurtalækningar studdir af vísindum
  • Jurtaviðurkenning eftir ímynd
  • Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
  • Lestu vísindarit sem tengjast leit þinni
  • Leitaðu að lækningajurtum eftir áhrifum þeirra
  • Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum

Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum

Google Play badgeApp Store badge